by Rod Raynovich | Apr 1, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Immucor (BLUD) a global leader in providing instrument-reagent systems to the blood transfusion industry delivered more than expected financial results for the 3rd Quarter of fiscal 2010 ended February 28. Revenue of $80.5M was up 7% from prior year quarter. Gross...
by Rod Raynovich | Mar 23, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The Raygent Model Portfolio was created in February 2009 and will be updated by the end of March 2010.The 14 month YTD performance is up 25%. New buys over past four months were Sequenom (SQNM) and SeraCare (SRLS). Currently under review are Immucor (BLUD) ,...
